 | |
| Clinical data | |
|---|---|
| Other names | AD-1211 |
| ATC code |
|
| Identifiers | |
| |
| CAS Number |
|
| PubChemCID | |
| ChemSpider |
|
| UNII | |
| CompTox Dashboard(EPA) | |
| Chemical and physical data | |
| Formula | C23H30N2O |
| Molar mass | 350.506 g·mol−1 |
| 3D model (JSmol) | |
| |
| |
| (verify) | |
AD-1211 is anopioidanalgesic drug invented in the 1970s byDainippon Pharmaceutical Co. It is chemically a 1-substituted-4-prenyl-piperazine derivative, which is structurally unrelated to most other opioid drugs. The (S)-enantiomers in this series are more active as opioid agonists, but the less active (R)-enantiomer of this compound, AD-1211, is a mixedagonist–antagonist at opioid receptors with a similar pharmacological profile topentazocine,[1] and has atypical opioid effects with little development oftolerance ordependence seen after extended administration in animal studies.[2][3]
